Opioids for Persistent Noncancer Pain

Medical Clinics of North America

Volumn 91, Issue 2, 2007, Pages 177-197

  McCleane, Gary ^a   Smith, Howard S ^b  

^a Rampark Pain Centre   (United Kingdom)

^b ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; BUPRENORPHINE; CALCIUM CHANNEL; CHOLECYSTOKININ; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CODEINE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; ENKEPHALIN; FENTANYL; FENTANYL CITRATE; GLUTAMIC ACID; HYDROMORPHONE; KETAMINE; MORPHINE; MORPHINE SULFATE; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; N METHYL DEXTRO ASPARTIC ACID; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXYCODONE; OXYMORPHONE; PARACETAMOL; PLACEBO; PROTEIN KINASE (CALCIUM,CALMODULIN) II; RAB PROTEIN; REMIFENTANIL; TESTOSTERONE; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; AMENORRHEA; ANALGESIA; ANDROGEN BLOOD LEVEL; ANTINOCICEPTION; CANCER PAIN; CELLULAR IMMUNITY; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DEPENDENCE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERANCE; DRUG WITHDRAWAL; ESTRADIOL BLOOD LEVEL; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERALGESIA; HYPOGONADOTROPIC HYPOGONADISM; IMPOTENCE; INNATE IMMUNITY; LIBIDO DISORDER; LONG TERM EXPOSURE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL IRREGULARITY; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NEUROPATHIC PAIN; NEUROTRANSMISSION; NONHUMAN; OPIOID INDUCED EMESIS; OSTEOARTHRITIS; PAIN; PAIN ASSESSMENT; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; REVIEW; SIDE EFFECT; SOMNOLENCE; SYNAPTIC TRANSMISSION; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME; VISUAL ANALOG SCALE; VOMITING;

ANALGESICS, OPIOID; CHRONIC DISEASE; DRUG TOLERANCE; DRUG UTILIZATION; HUMANS; PAIN; RECURRENCE; TIME FACTORS; TREATMENT FAILURE;

EID: 33847077642     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2006.10.013     Document Type: Review

References (73)

1. Olsen Y., Daumit G.L., and Ford D.E. Opioid prescriptions by US primary care physicians from 1992 to 2001. J Pain 7 (2006) 225-235
2. Won A., Lapane K.L., Vallow S., et al. Long-term effects of analgesics in a population of elderly nursing home residents with persistent non-malignant pain. J Gerontol A Biol Sci Med Sci 61 (2006) 165-169
3. Vestergaard P., Rejnmark L., and Mosekilde L. Fracture risk associated with the use of morphine and opiates. J Intern Med 260 (2006) 76-87
4. Kim K.S., Lee K.W., Lee K.W., et al. Adenylyl cyclase type 5 (AC5) is an essential mediator of morphine action. Proc Natl Acad Sci USA 103 (2006) 3908-3913
5. Berger B., Rothmaier A.K., Wedekind F., et al. Presynaptic opioid receptors on noradrenergic and serotonergic neurons in the human as compared to the rat neocortex. Br J Pharmacol 148 (2006) 795-806
6. Wang J.Y., Zhao M., Yuan Y.K., et al. The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model in rats. Neuroscience 138 (2006) 1319-1327
7. Chou R., Clark E., Helfan M., et al. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 26 (2003) 1026-1048
8. Portenoy R.K. Appropriate use of opioids for persistent non-cancer pain. Lancet 364 (2004) 739-740
9. A consensus statement prepared on behalf of the Pain Society, the Royal College of Aneasthetists, the Royal College of General Practitioners, and the Royal College of Psychiatrists. Recommendations for the appropriate use of opioids for persistent non-cancer pain, the Pain Society, London (March 2004). Available at: http://www.painsociety.org/pdf/opioids_doc_2004.pdf. Accessed August 9, 2004.
10. Kalso E., Allan L., Dellemijn P.L., et al. Recommendations for using opioids in chronic non-cancer pain. Eur J Pain 7 (2003) 381-386
11. Trescot A.M., Boswell M.V., Atluri S.L., et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 9 (2006) 1-39
12. A joint statement from 21 health organizations and the Drug Enforcement Administration. Promoting pain relief and preventing abuse of pain medications: a critical balancing act. Available at: http://www.medsch.wisc.edu/painpolicy/Consensus2.pdf. Accessed August 4, 2004.
13. World Health Organization. Achieving balance in national opioids control policy: guidelines for assessment. Available at: http://who.int/medicines.docs/pagespublications/qualitysafetypub.html.
14. Zacny J., Bigelow G., Compton P., et al. College on problems of drug dependence task force on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend 69 (2003) 215-232
15. Smith H.S. Goal-directed therapy agreements. Journal of Cancer Pain and Symptom Palliation 1 (2005) 11-13
16. Wasan A.D., Davar G., and Jamison R. The association between negative effect and opioid analgesia in patients with discogenic low back pain. Pain 177 (2005) 450-461
17. Eisenberg E., McNicol E.D., and Carr D.B. Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis trials. JAMA 293 (2005) 3043-3052
18. Kalso E., Edwards J.E., Moore R.A., et al. Opioids in chronic non-cancer pain: a systematic review of efficacy and safety. Pain 112 (2004) 372-380
19. Watson C.P., Watt-Watson J.H., and Chipman M.L. Chronic noncancer pain and the long term utility of opioids. Pain Res Manag 9 (2004) 19-24
20. Hassenbusch S.J., Portenoy R.K., Cousins M., et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intrapsinal drug delivery-report of an expert panel. J Pain Symptom Manage 27 (2004) 540-563
21. McCleane G.J. The role of cholecystokinin antagonists in human pain management: a review. Journal Neuropathic Pain Symptom Palliation 2 (2005) 37-44
22. McCleane G.J. Cholecystokinin antagonists: can they augment opioid-derived analgesia?. Journal Opioid Management 1 (2005) 273-279
23. Tang L., Shukla P.K., Wang L.X., et al. Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca (2 +)/calmodulin-dependent protein kinase II. J Pharmacol Exp Ther 317 (2006) 901-909
24. Bajo M., Crawford E.F., Roberto M., et al. Chronic morphine treatment alters expression of N-methyl-D-aspartate receptor subunits in the extended amygdala. J Neurosci Res 83 (2006) 532-537
25. Zhao M., and Joo D.T. Subpopulation of dorsal horn neurons displays enhanced N-methyl-D-aspartate receptor function after chronic morphine exposure. Anesthesiology 104 (2006) 815-825
26. Suzuki M., Narita M., Narita M., et al. Chronic morphine treatment increases the expression of vesicular glutamate transporter 1 in the mouse spinal cord. Eur J Pharmacol 535 (2006) 166-168
27. Johnson E.E., Chieng B., Napier I., et al. Decreased mu-opioid receptor signaling and a reduction in calcium current density in sensory neurons from chronically morphine-treated mice. Br J Pharmacol 148 (2006) 947-955
28. Ma J., and Pan Z.Z. Contribution of brainstem GABA (A) synaptic transmission to morphine analgesic tolerance. Pain 122 (2006) 163-173
29. Marquez P., Baliram R., Gajawada N., et al. Differential involvement of enkephalins in analgesic tolerance, locomotor sensitization, and conditioned place preference induced by morphine. Behav Neurosci 120 (2006) 10-15
30. Mao J. Opioid-induced abnormal pain sensitivity. Curr Pain Headache Rep 10 (2006) 67-70
31. Angst M.S., and Clarke J.D. Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 104 (2006) 570-587
32. Angst M.S., Koppert W., Pahl I., et al. Short-term infusion of the mu-opioid agonist remifentanil in humans causes hyperalgesia during withdrawal. Pain 106 (2003) 49-57
33. Hood D.D., Curry R., and Eisenach J.C. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 97 (2003) 810-815
34. Abs R., Verhelst J., Maeyaert J., et al. Endocrine consequences of long-term intrathecal administration of opioids. J Clin Endocrinol Metab 85 (2000) 2215-2222
35. Daniell H.W., Lentz R., and Mazer N.A. Open-label pilot study of testosterone patch therapy in men with opioid-induced androgen deficiency. J Pain 7 (2006) 200-210
36. Sacerdote P. Opioids and the immune system. Palliat Med 20S (2006) S9-S15
37. Ackerman S.J., Knight T., Schein J., et al. Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm 19 (2004) 118-132
38. Sittl R. Transdermal buprenorphine in cancer pain and palliative care. Palliat Med 20S (2006) S25-S30
39. Janicki P.K., and Parris W.C. Clinical Pharmacology of opioids. In: Smith H.S. (Ed). Drugs For Pain (2003), Hanley and Belfus, Philadelphia 97-118
40. Langford R., McKenna F., Ratcliffe S., et al. Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: A randomized, placebo-controlled trial. Arthritis Rheum 54 (2006) 1829-1837
41. Lichtor J.L., Sevarino F.B., Joshi G.P., et al. The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe post-operative pain. Anesth Analg 89 (1999) 732-738
42. Pather S.I., Siebert J.M., Hontz J., et al. Enhanced buccal delivery of fantanyl using the OraVescent drug delivery system. Drug Deliv Tech 1 (2001) 54-57
43. Durfee S., Messina J., and Khankari R. Fentanyl effervescent buccal tablets: enhanced buccal absorption. Am J Drug Deliv 4 (2006) 1-5
44. Lalovic B., Kharasch E., Hoffer C., et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 79 (2006) 461-479
45. Staahl C., Christrup L.L., Andersen S.D., et al. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 123 (2006) 28-36
46. Marshall D.A., Strauss M.E., Pericak D., et al. Economic evaluation of controlled-release oxycodone vs oxycodone-acetaminophen for osteoarthritis pain of the hip or knee. Am J Manag Care 12 (2006) 205-214
47. Cone E.J., Heit H.A., Caplan Y.H., et al. Evidence of morphine metabolism to hydromorphone in pain patients chronically treated with morphine. J Anal Toxicol 30 (2006) 1-5
48. Smith J., Owen E., Earis J., et al. Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease. J Allergy Clin Immunol 117 (2006) 831-835
49. Crawford M.W., Hickey C., Zaarour C., et al. Development of acute opioid tolerance during infusion of remifentanil for pediatric scoliosis surgery. Anesth Analg 102 (2006) 1662-1667
50. Childers S.R., Creese I., Snowman A.M., et al. Opiate receptor binding affected differentially by opiates and opioid pep tides. Eur J Pharmacol 55 (1979) 11-18
51. Gimbel J., and Ahdieh H. The efficacy and safety of oral immediate release oxymorphone for postsurgical pain. Anesth Analg 99 (2004) 1472-1477
52. Matsumoto A.K., Babul N., and Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized double-blind, placebo-and active-controlled phase III trial. Pain Med 6 (2005) 357-366
53. Gabrail N.Y., Dvergsten C., and Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with moderate to severe cancer pain. Curr Med Res Opin 20 (2004) 911-918
54. Hale M.E., and Dvergsten C. Gimbel. Efficacy and safety of oxymorphone extended release in chronic low back pain: results of a randomized, double-blind, placebo-and active-controlled phase III study. J Pain 6 (2005) 21-28
55. Sloan P., Slatkin N., and Ahdieh H. Effectiveness and safety of oral extended-release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 13 (2005) 57-65
56. Pharmaceuticals P. TIMERx control release delivery systems. Available at: http://www.penwest.com/timerx.html. Accessed January 10, 2005.
57. Adams M.P., and Ahdieh H. Pharmacokinetics and does-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 24 (2004) 468-476
58. Adams M.P., and Ahdieh H. Single- and multiple-dose pharmacokinetic and dose-proportionality study of oxymorphone immediate-release tablets. Drugs R D 6 (2005) 91-99
59. Lalovic B., Phillips B., Risler L.L., et al. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos 32 (2004) 447-454
60. McNichol E., Strassels S.A., Goudas L., et al. NSAIDs or paracetamol, alone or combined with opioids, for cancer pain. Cochrane Database Syst Rev 1 (2005) CD005180
61. McNichol E., Strassels S., Goudas L., et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. J Clin Oncol 22 (2004) 1975-1992
62. Reid C.M., Martin R.M., Sterne J.A., et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. Arch Intern Med 166 (2006) 837-843
63. Zeppetella G., and Ribeiro M.D. Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev 1 (2006) CD004311
64. Ballantyne J.C., and Carwood C.M. Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Cochrane Database Syst Rev 1 (2005) CD005178
65. Chou R., Clark E., and Helfand M. Comparative efficacy and safety of long-acting oral opioids for chronic non-cancer pain: a systematic review. J Pain Symptom Manage 28 (2004) 194-195
66. Furlan A.D., Sandoval J.A., Mailis-Gagnon A., et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. CMAJ 174 (2006) 1589-1594
67. Duhmke R.M., Cornblath D.D., and Hollingshead J.R. Tramadol for neuropathic pain. Cochrane Database Syst Rev 2 (2004) CD003726
68. Hempenstall K., Nurmikko T.J., Johnson R.W., et al. Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2 (2005) 164
69. Eisenberg E., McNichol E.D., and Carr D.B. Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: systematic review of randomized controlled trials. Eur J Pain 10 (2006) 667-676
70. Holdgate A., and Pollock T. Systematic review of the relative efficacy of non-steroidal anti-inflammatory drugs and opioids in the treatment of acute renal colic. BMJ 328 (2004) 1401
71. Rosseland L.A. No evidence for analgesic effect of intra-articular morphine after knee arthroscopy: a qualitative systematic review. Reg Anesth Pain Med 30 (2005) 83-98
72. Mercadante S., and Bruera E. Opioid switching: a systematic and critical review. Cancer Treat Rev 32 (2006) 304-315
73. Moore R.A., and McQuay H.J. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids. Arthritis Res Ther 7 (2005) 1046-1051